| Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2 J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, ... New England Journal of Medicine 369 (25), 2391-2405, 2013 | 2118 | 2013 |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and … F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ... Blood, The Journal of the American Society of Hematology 115 (9), 1703-1708, 2010 | 1067 | 2010 |
| Mutations and prognosis in primary myelofibrosis AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ... Leukemia 27 (9), 1861-1869, 2013 | 865 | 2013 |
| Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis A Tefferi, P Guglielmelli, DR Larson, C Finke, EA Wassie, L Pieri, ... Blood, The Journal of the American Society of Hematology 124 (16), 2507-2513, 2014 | 819 | 2014 |
| Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia AM Vannucchi, E Antonioli, P Guglielmelli, A Rambaldi, G Barosi, ... Blood, The Journal of the American Society of Hematology 110 (3), 840-846, 2007 | 633 | 2007 |
| The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion T Barbui, J Thiele, H Gisslinger, HM Kvasnicka, AM Vannucchi, ... Blood cancer journal 8 (2), 15, 2018 | 614 | 2018 |
| Effect of mutation order on myeloproliferative neoplasms CA Ortmann, DG Kent, J Nangalia, Y Silber, DC Wedge, J Grinfeld, ... New England Journal of Medicine 372 (7), 601-612, 2015 | 590 | 2015 |
| Classification and personalized prognosis in myeloproliferative neoplasms J Grinfeld, J Nangalia, EJ Baxter, DC Wedge, N Angelopoulos, R Cantrill, ... New England Journal of Medicine 379 (15), 1416-1430, 2018 | 556 | 2018 |
| Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia G Rotunno, C Mannarelli, P Guglielmelli, A Pacilli, A Pancrazzi, L Pieri, ... Blood, The Journal of the American Society of Hematology 123 (10), 1552-1555, 2014 | 512 | 2014 |
| MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis P Guglielmelli, TL Lasho, G Rotunno, M Mudireddy, C Mannarelli, ... Journal of Clinical Oncology 36 (4), 310-318, 2018 | 493 | 2018 |
| Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis E Rumi, D Pietra, C Pascutto, P Guglielmelli, A Martínez-Trillos, I Casetti, ... Blood, The Journal of the American Society of Hematology 124 (7), 1062-1069, 2014 | 475 | 2014 |
| Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden AM Vannucchi, E Antonioli, P Guglielmelli, G Longo, A Pancrazzi, ... Leukemia 21 (9), 1952-1959, 2007 | 473 | 2007 |
| Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments V De Stefano, T Za, E Rossi, AM Vannucchi, M Ruggeri, E Elli, C Micò, ... haematologica 93 (3), 372-380, 2008 | 396 | 2008 |
| IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis A Tefferi, TL Lasho, O Abdel-Wahab, P Guglielmelli, J Patel, ... Leukemia 24 (7), 1302-1309, 2010 | 381 | 2010 |
| Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal AM Vannucchi, E Antonioli, P Guglielmelli, A Pardanani, A Tefferi Leukemia 22 (7), 1299-1307, 2008 | 375 | 2008 |
| CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients A Tefferi, P Guglielmelli, TL Lasho, G Rotunno, C Finke, C Mannarelli, ... Leukemia 28 (7), 1494-1500, 2014 | 351 | 2014 |
| Advances in understanding and management of myeloproliferative neoplasms AM Vannucchi, P Guglielmelli, A Tefferi CA: a cancer journal for clinicians 59 (3), 171-191, 2009 | 348 | 2009 |
| Clinical implications of the JAK2 V617F mutation in essential thrombocythemia E Antonioli, P Guglielmelli, A Pancrazzi, C Bogani, M Verrucci, V Ponziani, ... Leukemia 19 (10), 1847-1849, 2005 | 346 | 2005 |
| The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients P Guglielmelli, TL Lasho, G Rotunno, J Score, C Mannarelli, A Pancrazzi, ... Leukemia 28 (9), 1804-1810, 2014 | 343 | 2014 |
| Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia AM Vannucchi, E Antonioli, P Guglielmelli, A Pancrazzi, V Guerini, ... Blood, The Journal of the American Society of Hematology 112 (3), 844-847, 2008 | 332 | 2008 |
